Notably, tumor therapeutic regimens targeting PI3K-mediated signaling pathways are currently a hot research topic at home and abroad, and inhibitors and activators targeting individual signaling molecules in the PI3K/Akt pathway are increasingly used in clinical trials [19, 20]. The gene discussed is AKT1; the disease is neoplasm.